Effect of intravenous infusion of omega-3 and omega-6 lipid emulsions on equine monocyte fatty acid composition and inflammatory mediator production in vitro.
The effect of intravenous administration of lipid emulsions enriched with omega-3 (n3) and omega-6 (n6) fatty acids on equine monocyte phospholipid fatty acid composition and the synthesis of inflammatory mediators in vitro was evaluated. In a randomized crossover design, horses were infused intravenously with 20% lipid emulsions containing n3 or n6 fatty acids. Monocytes were isolated from the horses before and 0 h, 8 h, 24 h, and 7 days after lipid infusion. Monocyte fatty acid analysis demonstrated incorporation of the parenteral n3 and n6 fatty acids in monocyte phospholipids immediately after infusion, with changes in the fatty acid composition persisting for up to 7 days after infusion. In vitro production of the inflammatory mediators thromboxane B2/thromboxane B3 (TXB(2/3)) and tumor necrosis factor-alpha (TNFalpha) by peripheral blood monocytes was diminished by n3 lipid infusion and was unchanged or increased by n6 lipid infusion. The results of this study demonstrate that short-term infusions of n3 and n6 fatty acid-enriched lipid emulsions alter the fatty acid composition of equine monocyte phospholipids and modify the inflammatory response of these cells in vitro. These results also support further investigation into the use of parenteral n3 fatty acids as part of the supportive therapy of patients with multiple organ dysfunction (MODS) or systemic inflammatory response syndrome (SIRS).
McCann
M E
ME
Department of Physiology, College of Veterinary Medicine, University of Georgia, Athens 30602, USA.
Moore
J N
JN
Carrick
J B
JB
Barton
M H
MH
D000818:Animals; D000001:Calcimycin / Q000494:pharmacology; D002478:Cells, Cultured; D018592:Cross-Over Studies; D004655:Emulsions; D019446:Endotoxemia / Q000378:metabolism / Q000662:veterinary; D005227:Fatty Acids / Q000097:blood*; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage / Q000494:pharmacology*; D043371:Fatty Acids, Omega-6; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006734:Horse Diseases / Q000378:metabolism; D006736:Horses; D007262:Infusions, Intravenous; D007476:Ionophores / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D008563:Membrane Lipids / Q000097:blood; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D010743:Phospholipids / Q000097:blood; D013929:Thromboxane B2 / Q000031:analogs & derivatives* / Q000096:biosynthesis* / Q000235:genetics; D013931:Thromboxanes / Q000031:analogs & derivatives*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis* / Q000235:genetics
D004655:Emulsions; D005227:Fatty Acids; D015525:Fatty Acids, Omega-3; D043371:Fatty Acids, Omega-6; D005231:Fatty Acids, Unsaturated; D007476:Ionophores; D008070:Lipopolysaccharides; D008563:Membrane Lipids; D010743:Phospholipids; D013931:Thromboxanes; D014409:Tumor Necrosis Factor-alpha; D000001:Calcimycin; D013929:Thromboxane B2; C039158:thromboxane B3